-
Company Insights
Innovation and Patenting activity of IP Group Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IP Group Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DSP-1083 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DSP-1083 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DSP-1083 in Parkinson's Disease Drug Details: DSP-1083 is under development for the...
-
Company Insights
Innovation and Patenting activity of Wonik IPS Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Wonik IPS Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-010 in Metastatic Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-010 in Metastatic Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-010 in Metastatic Ovarian Cancer Drug Details: PEP-010 (DPTC-9h) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PEP-010 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-010 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-010 in Pancreatic Ductal Adenocarcinoma Drug Details: PEP-010 (DPTC-9h) is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PEP-010 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PEP-010 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PEP-010 in Triple-Negative Breast Cancer (TNBC) Drug Details: PEP-010 (DPTC-9h)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Niraparib in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Niraparib in Endometrial Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Niraparib in Endometrial Cancer Drug Details: Niraparib (MK-4827, Zejula) is an...
-
Sector Analysis
Communications and Collaboration Market Size and Forecast (by Country, IT Solution Area, Size Band and Vertical) to 2027
Communications and Collaboration Market Overview The global communications and collaboration market size was valued at US$ 281.29 billion in 2022 and will grow at a compounded annual growth rate (CAGR) of 6.99% to reach US$ 394.31 billion by 2027. The cumulative revenue generation for communications and collaboration providers is estimated at US$ 1952.07 billion for 2022-2027. Communications and Collaboration Market Outlook, 2022-2027 (US$ Billion) Buy the Full Report for More Insights into the Communications and Collaboration Market Forecast Download a...
-
Sector Analysis
Managed Services Market Size and Forecast (by Country, IT Solution Area, Size Band and Vertical) to 2027
Managed Services Market Overview The managed services market size was valued at US$ 923.38 billion in 2022 and will grow at a compounded annual growth rate (CAGR) of 13.49% to reach US$ 1,738.51 billion by 2027. The cumulative revenue generation for managed services providers is estimated at US$ 7,615.11 billion for 2022-2027. Managed Services Market Outlook, 2022-2027 (US$ Billion) Buy the Full Report for More Insights into the Managed Services Market Forecast Download a Free Report Sample The ‘Managed Services...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pudafensine in Neuropathic Pain (Neuralgia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pudafensine in Neuropathic Pain (Neuralgia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pudafensine in Neuropathic Pain (Neuralgia) Drug Details: Pudafensine (IPED-2015) is under...